Arsenic Trioxide in Synergy with Vitamin D Rescues the Defective VDR-PPAR-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:math>Functional Module of Autophagy in Rheumatoid Arthritis

Weiyan Wang, Chunling Li, Zhiyi Zhang, Yue ZhangPPAR 2019 · DOI

TL;DR

This study reveals a defective autophagy pathway involving VDR and PPAR-γ in rheumatoid arthritis (RA) synovial cells. The researchers found that arsenic trioxide (ATO), alone or in combination with Vitamin D, can rescue this defect, reduce inflammation, and alleviate joint damage in RA models. This suggests a novel therapeutic strategy for RA.

What Problem Does This Paper Address?

Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes significant joint damage and disability. While autophagy, a cellular self-cleaning process, is known to be dysregulated in autoimmune diseases like RA, the precise molecular mechanisms and potential therapeutic targets within this pathway remain unclear. Specifically, the interplay between the Vitamin D receptor (VDR), peroxisome proliferator-activated receptor-gamma (PPAR-γ), and autophagy markers (LC3 and p62) in RA pathogenesis was not well understood. The paper aims to elucidate this relationship and explore the therapeutic potential of arsenic trioxide (ATO), a known anti-cancer agent, in modulating this pathway for RA treatment.

Methods

The study employed a multi-pronged approach combining in vitro and in vivo experiments:

  • Cell Culture: Rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) and normal human FLS were cultured and treated with TNF-α to mimic inflammatory conditions.
  • Molecular Analysis:
    • Real-time quantitative PCR (qPCR): To measure mRNA levels of VDR, PPAR-γ, LC3, p62, and mTOR.
  • Western Blotting: To assess protein expression levels of VDR, PPAR-γ, LC3 (LC3-I/II), p62, and mTOR.
  • RNA Interference (siRNA): To specifically knock down VDR expression and observe its impact on the autophagy module.
  • Animal Model: Collagen-induced arthritis (CIA) in DBA/1J mice was used to model RA.
  • In Vivo Treatments: CIA mice were treated with ATO, Vitamin D, or a combination thereof, as well as methotrexate (MTX) as a positive control.
  • Assessment of Arthritis:
    • Arthritis Severity Scoring: Clinical scoring of paw swelling and joint inflammation.
  • Microcomputed Tomography (micro-CT): To evaluate 3D bone structure and assess bone loss.
  • Histological Analysis: H&E staining of knee joints to score synovial hyperplasia, joint inflammation, and bone erosion.
  • Immunohistochemistry: To visualize the expression of VDR, PPAR-γ, LC3, and p62 in synovial tissues.
  • Enzyme-Linked Immunosorbent Assay (ELISA): To measure serum levels of inflammatory cytokines (IL-6, IL-1β, IL-8) and catabolic enzymes (MMP-3, MMP-13).

Datasets

Not discussed in the paper. The study utilizes cell lines and a mouse model of arthritis, rather than pre-existing public datasets.

Key Insights and Ideas

  • Defective Autophagy Module in RA: RA synovial fibroblasts exhibit an upregulated VDR-PPAR-γ-LC3 axis but paradoxically impaired autophagic flux, indicated by elevated p62 levels. This suggests a breakdown in the later stages of autophagy, not just induction.
  • ATO Rescues Autophagy: Arsenic trioxide (ATO) effectively rescues this defective autophagy module, both in vitro in RA FLS and in vivo in CIA mice. It achieves this by upregulating VDR, PPAR-γ, and LC3, while significantly downregulating p62.
  • Synergistic Effect of ATO and Vitamin D: Low-dose ATO combined with Vitamin D demonstrates a synergistic effect, achieving similar or even better results than higher doses of ATO alone in restoring the autophagy module and ameliorating RA symptoms. This is a crucial finding for potential therapeutic applications, as it could reduce ATO dosage and mitigate side effects.
  • Inhibition of Inflammation and Catabolism: ATO's rescue of the autophagy module is linked to the suppression of key inflammatory cytokines (IL-6, IL-1β, IL-8) and catabolic enzymes (MMP-3, MMP-13), which are critical drivers of joint destruction in RA.
  • PPAR-γ's Positive Feedback on VDR: In vitro experiments suggest that PPAR-γ activation by rosiglitazone can lead to elevated VDR expression, indicating a potential positive feedback loop within this functional module.

Key Results

  • In Vitro: ATO treatment (2 µM) in RA FLS significantly upregulated VDR, PPAR-γ, and LC3, while downregulating p62 (p<0.05). VDR knockdown exacerbated p62 levels, and ATO reversed this effect.
  • In Vivo (CIA Mice): ATO treatment (2 mg/kg/d) significantly increased VDR, PPAR-γ, and LC3 expression and decreased p62 in synovial tissue compared to saline-treated CIA mice (p<0.05).
  • Synergy: Combined ATO (low dose) and Vitamin D treatment showed comparable or enhanced effects to higher-dose ATO alone in upregulating VDR, PPAR-γ, and LC3 and downregulating p62 in vivo.
  • Symptom Alleviation: ATO and Vitamin D treatments significantly reduced arthritis scores, paw swelling, and body weight loss in CIA mice. The combination therapy further reduced arthritis scores.
  • Histological Improvement: ATO (2 mg/kg/d) and Vitamin D (400 ng/kg/d) significantly reduced histological scores for synovial hyperplasia, cartilage erosion, and joint inflammation.
  • Cytokine Reduction: ATO significantly suppressed the release of IL-6, IL-1β, IL-8, MMP-3, and MMP-13 in both in vitro (TNF-α induced) and in vivo (CIA mice serum) settings. The combination of ATO and Vitamin D showed synergistic effects in downregulating these factors.

Limitations and Future Work

  • Mechanisms: While the study demonstrates that ATO rescues the VDR-PPAR-γ autophagy functional module and inhibits inflammation, the precise molecular mechanisms underlying this rescue are still not fully understood.
  • Side Effects of ATO: The authors acknowledge that ATO has reported adverse effects (e.g., liver injury, carcinogenesis) in clinical settings, which limit its broader application. They suggest that local drug delivery, drug combinations, or chemical modifications could mitigate these issues.
  • Future Directions: The study highlights the potential of combining low-dose ATO with Vitamin D as a novel therapeutic strategy for RA. Further research could focus on optimizing the dosage and delivery methods for this combination therapy and investigating its long-term efficacy and safety profile. The paper also notes that the interrelationships between autophagy, angiogenesis, and apoptosis, which can be regulated by ATO, are areas for ongoing research.

Summary updated

Abstract

Dysregulated autophagy leads to autoimmune diseases including rheumatoid arthritis (RA). Arsenic trioxide (ATO) is a single agent used for the treatment of acute promyelocytic leukemia and is highly promising for other malignancies but is also attractive for RA, although its relationship with autophagy remains to be further clarified and its application optimized. For the first time, we report a defective functional module of autophagy comprising the Vitamin D receptor (VDR), PPAR-<i>γ</i>, microtubule-associated protein 1 light-chain 3 (LC3), and p62 which appears in RA synovial fibroblasts. ATO alleviated RA symptoms by boosting effective autophagic flux through significantly downregulating p62, the inflammation and catabolism protein. Importantly, low-dose ATO synergizes with Vitamin D in RA treatment.
BibTeX
@inproceedings{wang2019arsenic,
  author = {Weiyan Wang and Chunling Li and Zhiyi Zhang and Yue Zhang},
  title = {{Arsenic Trioxide in Synergy with Vitamin D Rescues the Defective VDR-PPAR-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:math>Functional Module of Autophagy in Rheumatoid Arthritis}},
  booktitle = {PPAR},
  year = {2019},
  doi = {10.1155/2019/6403504},
}
Figure